Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...

Researchers demonstrated that pancreatic β cells from type 2 diabetes donors can partially regain glucose responsiveness when ...

Please provide your email address to receive an email when new articles are posted on . Marked type 2 inflammation was present in eosinophilic cellulitis lesions. Preferential activation of the Janus ...

Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation - called tyrosine kinase 2 and Janus kinase 1 - and is being tested for the treatment of several immunological ...

Please provide your email address to receive an email when new articles are posted on . In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase 1 inhibitor ...

Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial ...

A Janus kinase (JAK) inhibitor helped preserve beta-cell function in people with recent-onset type 1 diabetes, the phase II BANDIT trial found. Meeting the study's primary endpoint, daily baricitinib ...